BioCryst Pharmaceuticals Price Target Raised to $19.00/Share From $14.00 by HC Wainwright & Co.
BioCryst Pharmaceuticals analyst ratings
HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $19
BioCryst To Start Pivotal BCX9930 Trial In Rare Blood Disorder In 2H'21
12 Health Care Stocks Moving In Monday's Pre-Market Session
BioCryst's Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial
BioCryst Pharmaceuticals shares are trading higher ahead of the company's expected phase 1 clinical trial data for BCX9930.
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
BRIEF-Biocryst Pharmaceuticals - On March 18, Co Withdrew Its Application For Orphan Medicinal Product Designation For Orladeyo
BioCryst Pharmaceuticals stock price target raised to $15 from $10 at J.P. Morgan